Liraglutide 16 IU Cinnagen

Description

Liraglutide 16 IU Cinnagen — liraglutide from Cinnagen at 16 iu. Daily GLP-1 receptor agonist. Same class as semaglutide with shorter action — daily injection schedule. Clinically approved for obesity (Saxenda brand at 3 mg).

Key Benefits

• GLP-1 receptor agonist — mimics the gut-hormone incretin pathway
• Appetite suppression and delayed gastric emptying for sustained satiety
• Weekly subcutaneous dosing; steady titration schedule
• Clinical data: 10–15% body-weight reduction over 68 weeks at therapeutic dose
• HbA1c reduction alongside weight loss — dual metabolic benefit
• Each unit dosed at 16 IU — see Recommended Dosage below for protocol-specific intake

How It Works

Long-acting glucagon-like-peptide-1 (GLP-1) receptor agonist. Binds GLP-1 receptors in pancreatic β-cells (glucose-dependent insulin release), hypothalamus (appetite suppression), and GI tract (delayed gastric emptying). Albumin binding via palmitic-acid side chain extends half-life to allow weekly dosing.

Pharmacokinetics

Plasma half-life approximately 7 days — once-weekly SubQ dosing produces stable exposure. Steady-state reached at 4–5 weeks. Abdominal or thigh subcutaneous injection. Reconstituted vial stable in fridge for 56 days.

Potential Side Effects

GI side-effects dominant: nausea, early satiety, occasional vomiting — worst during dose-escalation weeks, attenuate at maintenance. Pancreatitis rare but documented. Gallbladder events at higher doses. Muscle-mass loss alongside fat loss — resistance training during protocol essential.

Cycle & Stacking Guide

12–24 week protocols typical for weight-focus use. Titrate up slowly to minimise GI side-effects. Stack with resistance training + adequate protein (1.6–2.0 g/kg bodyweight) to preserve lean mass. Discontinuation rebound: ~2/3 of weight loss returns within 1 year without metabolic maintenance protocol.

Manufacturer Notes

Cinnagen is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.